This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haffajee, C. I. Articles by Alpert, J. S. Search for Related Content PubMed PubMed Citation Articles by Haffajee, C. I. Articles by Alpert, J. S.

Circulation, Vol 67, 1347-1355, Copyright © 1983 by American Heart Association

ARTICLES

Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias

CI Haffajee, JC Love, AT Canada, LJ Lesko, G Asdourian and JS Alpert

Using a high-pressure liquid chromatographic assay, we measured serum amiodarone concentrations serially in 122 patients treated with amiodarone for 1.5-53 months (mean 9.3 months) for control of refractory symptomatic atrial or symptomatic and life-threatening ventricular tachyarrhythmias. The atrial tachyarrhythmias were successfully controlled in 45 of 54 patients (83%) during a mean follow- up of 10.0 months. In the ventricular tachyarrhythmia group, which included 22 survivors of sudden cardiac death, 38 of 50 patients (76%) responded to amiodarone during a mean follow-up of 10.9 months. Although the mean serum amiodarone concentration did not differ between responders and nonresponders, eight responders relapsed when their serum concentration fell below 1.0 mg/l. Side effects resulted in withdrawal of amiodarone in only 10 of 122 patients (9%) despite a 30% overall incidence of side effects. Central nervous system and gastrointestinal side effects became more frequent with serum concentrations greater than 2.5 mg/l, although only central nervous system side effects achieved statistical significance. Absorption and disposition kinetics of a single oral 800-mg dose of amiodarone were studied in eight patients. Serum values were measured for 24 hours in five patients during maintenance therapy, and elimination kinetics after long-term therapy were evaluated in three patients. The tissue concentration of amiodarone was determined in two patients who died during long-term amiodarone therapy and an attempt was made in 14 patients to correlate serum concentrations with daily dosages during maintenance therapy. The pharmacokinetics of oral amiodarone support the practice of using high loading dosages until arrhythmia suppression or apparent steady state is achieved (usually 2-4 weeks), followed by low-dose maintenance therapy (200-600 mg once a day) for treatment of symptomatic atrial and ventricular tachyarrhythmias.

This article has been cited by other articles:

				J. G Kendrick, J. J Macready, and N. Kissoon Amiodarone Treatment of Junctional Ectopic Tachycardia in a Neonate Receiving Extracorporeal Membrane Oxygenation Ann. Pharmacother., October 1, 2006; 40(10): 1872 - 1875. [Abstract] [Full Text] [PDF]

				S. Tedelind, F. Larsson, C. Johanson, H. C. van Beeren, W. M. Wiersinga, E. Nystrom, and M. Nilsson Amiodarone Inhibits Thyroidal Iodide Transport in Vitro by a Cyclic Adenosine 5'-Monophosphate- and Iodine-Independent Mechanism Endocrinology, June 1, 2006; 147(6): 2936 - 2943. [Abstract] [Full Text] [PDF]

				M. C. Ott, A. Khoor, J. P. Leventhal, T. E. Paterick, and C. D. Burger Pulmonary Toxicity in Patients Receiving Low-Dose Amiodarone Chest, February 1, 2003; 123(2): 646 - 651. [Abstract] [Full Text] [PDF]

				S. J. Connolly Evidence-Based Analysis of Amiodarone Efficacy and Safety Circulation, November 9, 1999; 100(19): 2025 - 2034. [Full Text] [PDF]

				J. Wolff Perchlorate and the Thyroid Gland Pharmacol. Rev., March 1, 1998; 50(1): 89 - 106. [Abstract] [Full Text] [PDF]

				M. A. Hollinger Drug-Induced Lung Toxicity International Journal of Toxicology, January 1, 1993; 12(1): 31 - 47. [Abstract] [PDF]

				A. T. M. Gosselink, H. J. G. M. Crijns, I. C. Van Gelder, H. Hillige, A. C. P. Wiesfeld, and K. I. Lie Low-Dose Amiodarone for Maintenance of Sinus Rhythm After Cardioversion of Atrial Fibrillation or Flutter JAMA, June 24, 1992; 267(24): 3289 - 3293. [Abstract] [PDF]

				R. D. Blevins, N. Z. Kerin, D. Benaderet, H. Frumin, K. Faitel, R. Jarandilla, and M. Rubenfire Amiodarone in the Management of Refractory Atrial Fibrillation Arch Intern Med, August 1, 1987; 147(8): 1401 - 1404. [Abstract] [PDF]

				B. RIGAS, L. E. ROSENFELD, K. W. BARWICK, R. ENRIQUEZ, J. HELZBERG, W. P. BATSFORD, M. E. JOSEPHSON, and C. A. RIELY Amiodarone Hepatotoxicity: A Clinicopathologic Study of Five Patients Ann Intern Med, March 1, 1986; 104(3): 348 - 351. [Abstract] [PDF]